DCOY

SCHEDULE 13G - Decoy Therapeutics Inc. (0001615219) (Subject)

10-Q - Decoy Therapeutics Inc. (0001615219) (Filer)

DEF 14A - Decoy Therapeutics Inc. (0001615219) (Filer)

DEFA14A - Decoy Therapeutics Inc. (0001615219) (Filer)

Portfolio now spans seven patent families and 19 pending applications across seven jurisdictions, protecting antiviral peptide conjugates, the methods used to make them, their formulations, and the design platform behind themCAMBRIDGE, Mass., Aug. 3, 2026 /PRNewswire/ -- Decoy Therapeutics Inc. (NASDAQ:DCOY), a biotechnology company developing Designable Multi-Antivirals (D-MAVs™), today announced continued expansion of its intellectual property portfolio, which now comprises seven patent families covering compositions of matter, methods of manufacture, formulations, and the company's IMP³ACT™ design platform. The portfolio inc

3 - Decoy Therapeutics Inc. (0001615219) (Issuer)

Lead D-MAV demonstrates cross-viral family fusion inhibition, validating theplatform; opens a new program in filovirus pandemic preparednessCAMBRIDGE, Mass., July 27, 2026 /PRNewswire/ -- Decoy Therapeutics Inc. (NASDAQ:DCOY), a biotechnology company developing Designable Multi-Antivirals (D-MAVs™), today announced that one of its D-MAV candidates demonstrates in vitro activity against wild-type Ebola Zaire virus in testing at the Texas Biomedical Research Institute. Building on the result, Decoy has opened an exploratory program to design D-MAVs against filoviruses, including Ebola and Marburg. The candidate was engineered on

PRE 14A - Decoy Therapeutics Inc. (0001615219) (Filer)

EFFECT - Decoy Therapeutics Inc. (0001615219) (Filer)

424B3 - Decoy Therapeutics Inc. (0001615219) (Filer)

8-K - Decoy Therapeutics Inc. (0001615219) (Filer)

CAMBRIDGE, Mass., July 15, 2026 /PRNewswire/ -- Decoy Therapeutics Inc. (NASDAQ:DCOY), a biotechnology company pioneering Designable Multi-Antivirals (D-MAVs™), a new category of antivirals engineered to target shared viral mechanisms, today announced that stockholders elected Patricia Gauthier, MBA, LL.B., as a Class II director at the Company's 2026 Annual Meeting of Stockholders, held July 14, 2026 Ms. Gauther will serve with the Company's other two Class II directors, Rick Pierce and Jon Lieber, each of whom were re-elected at the annual meeting. "Patricia has spent her career making sure important medicines reach the peopl

S-1 - Decoy Therapeutics Inc. (0001615219) (Filer)

DENVER, June 29, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) – As the second half of 2026 begins, a series of regulatory approvals, strategic acquisitions, clinical development milestones, and financing initiatives are highlighting continued activity across the biotechnology and healthcare sectors, as companies work to expand pipelines, strengthen balance sheets, and advance toward commercialization. Universe Pharmaceuticals (NASDAQ:UPC) announced a definitive agreement to acquire Best Praise International Limited, a transaction that would add five China-based pharmaceutical patents to the company's intellectual property portfolio. The all-stock acquisition, valued at approximately $10.7

8-K - Decoy Therapeutics Inc. (0001615219) (Filer)

HOUSTON, June 26, 2026 /PRNewswire/ -- Decoy Therapeutics, Inc. (NASDAQ:DCOY) (the "Company" or "Decoy"), a biotechnology company pioneering Designable Multi-Antivirals (D-MAVs™), a new category of antivirals engineered to target shared viral mechanisms conserved across virus families, today announced that it has entered into a securities purchase agreement with a single healthcare focused institutional investor for a private investment in public equity financing (the "PIPE"), which is expected to provide approximately $3.5 million in gross proceeds at closing, before deducting placement agent's fees and other financing expenses payable by the Company. The Company intends to use the net proc

EFFECT - Decoy Therapeutics Inc. (0001615219) (Filer)

Rick Pierce to join speakers from Boehringer Ingelheim, RA Capital and ILiAD Biotechnologies for discussion on early clinical development CAMBRIDGE, Mass., June 8, 2026 /PRNewswire/ -- Decoy Therapeutics, Inc. (NASDAQ:DCOY), a biotechnology company pioneering Designable Multi-Antivirals (D-MAVs™), a new category of antivirals engineered to target shared viral mechanisms conserved across virus families, today announced that Chief Executive Officer Rick Pierce will speak at the Capital Markets Day hosted by hVIVO plc (AIM: HVO) on June 11, 2026 in Canary Wharf, London. The half-day event brings together analysts, institutional in

RW - Decoy Therapeutics Inc. (0001615219) (Filer)

DEFA14A - Decoy Therapeutics Inc. (0001615219) (Filer)

DEF 14A - Decoy Therapeutics Inc. (0001615219) (Filer)

CAMBRIDGE, Mass., June 3, 2026 /PRNewswire/ -- Decoy Therapeutics Inc. (NASDAQ:DCOY), a biotechnology company pioneering Designable Multi-Antivirals (D-MAVs™), a new category of antivirals engineered to target shared viral mechanisms, today announced the nomination of Patricia Gauthier, MBA, LL.B., as a Class II director. Ms. Gauthier's nomination will be voted on at the Company's 2026 Annual Meeting of Stockholders on July 14, 2026. "Patricia has spent her career making sure important medicines reach the people who need them, at scale and in the real world. As we advance our D-

Collaboration supports Phase 1 and Phase 2a human proof-of-concept studies for new antiviral category designed to address multiple viruses with a single adaptable therapeuticCAMBRIDGE, Mass., June 1, 2026 /PRNewswire/ -- Decoy Therapeutics Inc. (NASDAQ:DCOY), a pre-clinical-stage biotechnology company pioneering a new category of antivirals, today announced the execution of a strategic development initiative designed to support the advancement of the company's Designable Multi-Antiviral (D-MAV) candidates into Phase 1 first-in-human and Phase 2a human proof-of-concept studies. D

Appointment deepens scientific leadership as Decoy advances its Designable Multi-Antiviral pipeline toward clinical developmentNEW YORK and CAMBRIDGE, Mass., May 26, 2026 /PRNewswire/ -- Decoy Therapeutics Inc. (NASDAQ:DCOY), a clinical-stage biotechnology company pioneering a new category of antivirals, today announced the appointment of Brad L. Pentelute, Ph.D., Professor of Chemistry at the Massachusetts Institute of Technology, as Chair of its Scientific Advisory Board (SAB). Dr. Pentelute is an original co-founder of Decoy and has served as a Technology Advisor since the company's inception. He is widely recognized for his foundational contributions to peptide synthesis and protein engi

8-K - Decoy Therapeutics Inc. (0001615219) (Filer)